Literature DB >> 21427585

Salvage lymphadenectomy in postprostatectomy patients with prostate-specific antigen recurrence.

Nazareno Suardi1, Alberto Briganti, Andrea Salonia, Patrizio Rigatti.   

Abstract

PURPOSE OF REVIEW: Despite very good oncological outcomes provided by radical prostatectomy for organ-confined prostate cancer, up to 40% of patients develop a biochemical recurrence (BCR). BCR can be associated with local or distant recurrence of prostate cancer. However, it can be difficult to identify the exact site of recurrence based on traditional diagnostic imaging tools. The introduction of more advanced imaging studies, such as PET/computed tomography scan, has led to the possibility of identifying small sites of recurrence of prostate cancer. Therefore, once the exact site of recurrence has been identified, theoretically new treatment options might be introduced. RECENT
FINDINGS: Few studies have addressed the possibility to perform a selective pelvic/retroperitoneal lymph node dissection in patients with BCR associated with the evidence of nodal uptake at PET/computed tomography scan. The results of such studies are conflicting, since some patients seem to benefit from the removal of recurrent lymph nodes, showing temporary prostate-specific antigen response to salvage surgery. On the other hand, other series showed no benefit for such patients related to this surgical approach. Moreover, the identification of the good candidates to salvage lymph node dissection is needed.
SUMMARY: Few studies reported a partial or even a complete prostate-specific antigen response to salvage lymph node dissection in patients with nodal recurrence of prostate cancer. However, due to the small number of patients included, to the lack of control groups as well as to the short-term follow-up, to date the available data do not justify the use of this surgical approach out of clinical trials.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21427585     DOI: 10.1097/MOU.0b013e328344e4c4

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  5 in total

Review 1.  PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.

Authors:  Giampiero Giovacchini; Elisabetta Giovannini; Rossella Leoncini; Mattia Riondato; Andrea Ciarmiello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-14       Impact factor: 9.236

2.  Is there a role for salvage lymphadenectomy as second line therapy post robotic radical prostatectomy?

Authors:  Sanchia Goonewardene; D Cahill
Journal:  J Robot Surg       Date:  2016-04-15

3.  (11)C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients.

Authors:  M Picchio; G Berardi; A Fodor; E Busnardo; C Crivellaro; G Giovacchini; C Fiorino; M Kirienko; E Incerti; C Messa; L Gianolli; N Di Muzio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-03-06       Impact factor: 9.236

4.  Cancer-specific and overall survival in patients with recurrent prostate cancer who underwent salvage extended pelvic lymph node dissection.

Authors:  Daniar K Osmonov; Alexey V Aksenov; David Trick; Carsten M Naumann; Moritz F Hamann; Amr Abou Faddan; Klaus-Peter Jünemann
Journal:  BMC Urol       Date:  2016-09-06       Impact factor: 2.264

Review 5.  Oligometastases in prostate cancer: restaging stage IV cancers and new radiotherapy options.

Authors:  Antonio José Conde Moreno; Carlos Ferrer Albiach; Rodrigo Muelas Soria; Verónica González Vidal; Raquel García Gómez; María Albert Antequera
Journal:  Radiat Oncol       Date:  2014-12-11       Impact factor: 3.481

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.